Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany
Introduction
Patients are showing an increasing interest in the use of complementary and alternative treatment methods (CAMs) in the treatment of acute and chronic diseases,1, 2 both in adults3, 4 and in children5, 6, 7 and particularly in the Western industrial nations.8 Professional organisations such as medical societies and the WHO9, 10, 11 are also devoting increasing attention to traditional and complementary medicine in the scientific debate. In adult oncology CAM is used to a significant extent.12, 13 Depending on the population studied, the prevalence of use is well above 50%14, 15, 16 and in all populations a trend towards increasing prevalence of use over time can be seen.17 Many of the CAMs used have not yet been scientifically studied or only to an insufficient extent. So far only a few smaller studies have been published on the prevalence of the use of CAM in children with cancer and factors related to its use.18, 19, 20, 21, 22, 23, 24, 25, 26 With sometimes very different study populations and in the absence of a uniform definition of CAM there is considerable variation in the reported prevalences of CAM use and the related factors. The largest population based study published to date18 reported a prevalence of CAM use of 42% for British Columbia/Canada. There are practically no representative data available on the prevalence of CAM use in Europe. Only Molassiotis and colleagues14 have reported a prevalence of 33% in the United Kingdom. To date there are no figures on CAM use in children with cancer in Germany. In view of the general increase in the prevalence of CAM and the fact that very little is known about the effects and side-effects of these methods there is an urgent need for better investigation of these treatment strategies.
As the first step we now present the first nationwide, registry-based, population-based retrospective survey of the prevalence of CAMs use in children with cancer, the types of therapies used and the factors related to its use.
The data obtained in our survey provide a basis for subsequent prospective studies on the use particularly of the more frequently used CAM methods in paediatric oncology. They can also serve as a source of information for paediatric oncologists around the world as an opening for frank and competent dialogue with parents of children with cancer on the subject of CAM.
Section snippets
Selection of patients
The survey was conducted from 1st of January to 15th September 2004. All families with a child under the age of 15 years who was first diagnosed with a disease defined in the International Childhood Cancer Classification (ICCC)27 or with myelodysplastic syndrome (MDS), severe aplastic anaemia (SAA) or Langerhans cell histiocytosis (LCH) between 1st of January and 31st December 2001 and registered in the German Childhood Cancer Registry (GCCR), were eligible for inclusion. Approximately 95% of
Patient characteristics
Eighty of the Eighty one German hospitals which had reported cases to the GCCR during the period in question, consented in principle to include their patients in the survey. A total of 79 patients were excluded by the hospitals from the survey (the most frequently given reasons were, in decreasing order of frequency: death of the patient, language problems and patient had left Germany). Of the 1768 patients registered in the GCCR in the year 2001 (time of first diagnosis) who met the inclusion
Discussion
This is the most extensive as well as the first population-based study on the prevalence of use of CAM in paediatric oncology. Only one small study from Canada18 with 44 interviewees was based on a cancer registry. The prevalence of CAM use in our survey population was 35%. The very narrow confidence interval [31.7%; 37.4%] and the high statistical power of the study on account of the sample size can be taken to indicate that the figure found for the prevalence of use is very reliable. The
Conflict of interest statements
Alfred Laengler has got honoraria for lectures held for anthroposophic pharmaceutical companies (WELEDA, Helixor).
Claudia Spix: no conflict of interest.
Georg Seifert is running a clinical study sponsored by anthroposophic pharmaceutical companies (Wala, WELEDA, Helixor).
Sven Gottschling: no conflict of interest.
Norbert Graf: no conflict of interest.
Peter Kaatsch: no conflict of interest.
Authors contributions
Alfred Laengler designed the study, was involved in the conception of the questionnaire, did the data analysis, interpretation and wrote the manuscript.
Claudia Spix was involved in the study and questionnaire conception, data management and did the statistical analysis. She participated in writing the manuscript.
Georg Seifert was involved in the study conception and data analysis. He participated in writing the manuscript.
Sven Gottschling was involved in the study and questionnaire conception
Acknowledgements
We would like to thank Ms Irene Jung of the GCCR for her excellent support with the distribution of the questionnaire and with the data logistics and analysis, Barbara Pfrengle-Längler for her help with the data input, the hospitals and particularly the families participating in the survey. We would also like to express our thanks to Prof Dr. H. Jürgens and Prof. Dr. F. Berthold for their kind support of the project in the Society of Paediatric Oncology and Haematology (GPOH). The study
References (43)
The role of complementary and alternative medicine in cancer
Lancet Oncol
(2000)- et al.
‘Thinking outside the box’: complementary and alternative therapies use in paediatric oncology patients
Eur J Oncol Nurs
(2004) - et al.
Complementary and alternative medicine (CAM): epidemiology and implications for research
Prog Brain Res
(2000) - et al.
Unconventional therapies for cancer and cancer-related symptoms
Lancet Oncol
(2001) - et al.
Unconventional therapy use among children with cancer in Saskatchewan
J Pediatr Oncol Nurs
(2001) - et al.
Use of alternative medicine by children with cancer in Washington state
Prev Med
(2001) - Allensbacher Archiv (2002). Naturheilmittel 2002. Allensbach: Allensbach...
- Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review....
- et al.
Consulting a complementary and alternative medical practitioner: a systematic inventory of motives among French patients
J Altern Complement Med
(2006) - et al.
Complementary and conventional medicine in Switzerland: comparing characteristics of general practitioners
Forsch Komplementarmed
(2006)
The use of complementary and alternative medicine among pediatric patients
Cancer Nurs
Survey of paediatric complementary and alternative medicine use in health and chronic illness
Arch Dis Child
Complementary therapy use by patients and parents of children with asthma and the implications for NHS care: a qualitative study
BMC Health Serv Res
The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004
Med J Aust
Complementary and alternative medicine research initiatives in the Children’s Oncology Group and the role of the pediatric oncology nurse
J Pediatr Oncol Nurs
Children’s Oncology Group. Complementary and alternative medicine in pediatric oncology: availability and institutional policies in Canada – a report from the Children’s Oncology Group
Pediatr Blood Cancer
The prevalence of complementary/alternative medicine in cancer: a systematic review
Cancer
Long-term trends in the use of complementary and alternative medical therapies in the United States
Ann Intern Med
Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse
J Clin Oncol
Use of alternative therapies for children with cancer
Pediatrics
Cited by (82)
Perception of integrative care in paediatric oncology—perspectives of parents and patients
2021, Complementary Therapies in MedicineIntegrative care for children with cancer. Project design for the development of an integrative care programme for use in paediatric oncology
2018, Complementary Therapies in MedicineTaraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy
2018, Complementary Therapies in MedicineSafety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series
2018, Complementary Therapies in MedicineComplementary and alternative medicine (CAM) is frequently used by parents for the treatment of functional constipation in children
2024, Journal of Pediatric Gastroenterology and Nutrition